These agents show limited specificity, compared with the other two types of inhibitors discussed earlier; however, they have demonstrated potential to regulate the NLRP3 inflammasome as NAFLD treatment in clinical and animal studies. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatotic liver disease.